Monthly migraine days, tablet utilization, and quality of life associated with Rimegepant – post hoc results from an open label safety study (BHV3000–201)

BACKGROUND: The objective of this study was to describe patterns in monthly migraine days (MMD) and tablet utilization, and to estimate health-related quality of life (HRQoL) measures in patients treated as needed (PRN) with rimegepant 75 mg over 52-weeks. METHODS: Eligible subjects were adults with...

Descripción completa

Detalles Bibliográficos
Autores principales: Johnston, Karissa, Harris, Linda, Powell, Lauren, Popoff, Evan, Coric, Vladimir, L’Italien, Gilbert, Schreiber, Curtis P.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer Milan 2022
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8903552/
https://www.ncbi.nlm.nih.gov/pubmed/35038983
http://dx.doi.org/10.1186/s10194-021-01378-5

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8903552/
https://www.ncbi.nlm.nih.gov/pubmed/35038983
http://dx.doi.org/10.1186/s10194-021-01378-5

Ejemplares similares